512 related articles for article (PubMed ID: 28103901)
1. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
[TBL] [Abstract][Full Text] [Related]
2. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway.
Salašová A; Yokota C; Potěšil D; Zdráhal Z; Bryja V; Arenas E
Mol Neurodegener; 2017 Jul; 12(1):54. PubMed ID: 28697798
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model.
Wetzel A; Lei SH; Liu T; Hughes MP; Peng Y; McKay T; Waddington SN; Grannò S; Rahim AA; Harvey K
Sci Rep; 2024 May; 14(1):12393. PubMed ID: 38811759
[TBL] [Abstract][Full Text] [Related]
4. High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity.
Guttuso T
Med Hypotheses; 2019 Oct; 131():109302. PubMed ID: 31443765
[TBL] [Abstract][Full Text] [Related]
5. The role of LRRK2 in cell signalling.
Harvey K; Outeiro TF
Biochem Soc Trans; 2019 Feb; 47(1):197-207. PubMed ID: 30578345
[TBL] [Abstract][Full Text] [Related]
6. Lrrk2 modulation of Wnt signaling during zebrafish development.
Wint JM; Sirotkin HI
J Neurosci Res; 2020 Oct; 98(10):1831-1842. PubMed ID: 32623786
[TBL] [Abstract][Full Text] [Related]
7. Identification of Targets from LRRK2 Rescue Phenotypes.
Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
[TBL] [Abstract][Full Text] [Related]
8. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6.
Berwick DC; Harvey K
Hum Mol Genet; 2012 Nov; 21(22):4966-79. PubMed ID: 22899650
[TBL] [Abstract][Full Text] [Related]
12. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
Nixon-Abell J; Berwick DC; Harvey K
Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
Sancho RM; Law BM; Harvey K
Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
Elife; 2020 Feb; 9():. PubMed ID: 32057291
[TBL] [Abstract][Full Text] [Related]
15. Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.
Nixon-Abell J; Berwick DC; Grannó S; Spain VA; Blackstone C; Harvey K
Front Mol Neurosci; 2016; 9():18. PubMed ID: 27013965
[TBL] [Abstract][Full Text] [Related]
16. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
18. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
19. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
20. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
Elife; 2020 Oct; 9():. PubMed ID: 33006315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
